Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

NCT03464097 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT03464097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03464097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Terminated
Start date
June 27, 2018
Completion date
October 3, 2024
Enrollment
550 (actual)
Sites
765

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease